Q/C Technologies, Inc. Derivative Liability, Fair Value of Collateral
Q/C Technologies, Inc. (QCLS) had Derivative Liability, Fair Value of Collateral of $100.00 thousand as of 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Notes
us-gaap:DerivativeLiabilityFairValueOfCollateral · last filed 2023-05-15
- 2023-03-31: Derivative Liability, Fair Value of Collateral $100.00K.
| Period end | Derivative Liability, Fair Value of Collateral |
|---|---|
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |